Dachaigh › Aillse Sgamhain Neo-chealla-beag › California › Mountain View
Sgrùdaidhean clionaigeach Aillse Sgamhain Neo-chealla-beag ann an Mountain View, CA
Tha 21 sgrùdaidhean airson Aillse Sgamhain Neo-chealla-beag a’ lorg phàirtichean aig làraichean ann agus timcheall air Mountain View (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
A’ fastadhÌre 1/2
- Stanford Cancer Institute (Melanoma/NSCLC), Stanford · 5 mìle air falbh
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
A’ fastadhÌre 3
- Palo Alto Medical Foundation-Camino Division, Mountain View
- Palo Alto Medical Foundation Health Care, Palo Alto · 5 mìle air falbh
- Stanford Cancer Institute Palo Alto, Palo Alto · 5 mìle air falbh
Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC
A’ fastadhÌre 3
- Stanford University, Stanford · 5 mìle air falbh
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
A’ fastadhÌre 2
- Stanford Cancer Institute, Stanford · 5 mìle air falbh
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
A’ fastadhSgrùdadh amharc
- Stanford University, Palo Alto · 5 mìle air falbh
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
A’ fastadhÌre 2
- Stanford Cancer Institute, Stanford · 5 mìle air falbh
- Stanford Hospital and Clinics, Stanford · 5 mìle air falbh
- Stanford Hospital Investigational Drug Services, Stanford · 5 mìle air falbh
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
A’ fastadhÌre 3
- Stanford Cancer Center, Palo Alto · 5 mìle air falbh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
A’ fastadhÌre 1/2
- Stanford Cancer Institute, Stanford · 5 mìle air falbh
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
A’ fastadhÌre 1/2
- Stanford University Medical Center - Neurology, Stanford · 5 mìle air falbh
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
A’ fastadhÌre 3
- Palo Alto Medical Foundation Research Center, Palo Alto · 5 mìle air falbh
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
A’ fastadhÌre 1/2
- Stanford Cancer Institute, Stanford · 5 mìle air falbh
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
A’ fastadhÌre 1/2
- Stanford University Medical Center, Stanford · 5 mìle air falbh
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
A’ fastadhÌre 1
- Stanford University Medical Center, Palo Alto · 5 mìle air falbh
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
A’ fastadhÌre 1
- Stanford University, Palo Alto · 5 mìle air falbh
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
A’ fastadhÌre 1/2
- Stanford University - Stanford Cancer Institute, Stanford · 5 mìle air falbh
A Study of LY4175408 in Participants With Advanced Cancer
A’ fastadhÌre 1
- Stanford Medicine Cancer Center, Stanford · 5 mìle air falbh
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
A’ fastadhÌre 1/2
- Stanford University, Stanford · 5 mìle air falbh
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
A’ fastadhÌre 1/2
- Stanford Women's Cancer Center, Palo Alto · 5 mìle air falbh
Engagement of Veterans With Lung Cancer
A’ fastadh
- Veterans Affairs Palo Alto Health Care System (VAPAHCS), Palo Alto · 5 mìle air falbh
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
A’ fastadhSgrùdadh amharc
- Massive Bio SYNERGY-AI site, Stanford · 5 mìle air falbh
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
A’ fastadhÌre 1
- Stanford University, Stanford · 5 mìle air falbh
Sgrùdaidhean Aillse Sgamhain Neo-chealla-beag ann am bailtean eile
- Houston, TX145 sgrùdaidhean
- New York City, NY121 sgrùdaidhean
- Arlington, VA104 sgrùdaidhean
- Nashville, TN97 sgrùdaidhean
- Boston, MA90 sgrùdaidhean
- Los Angeles, CA87 sgrùdaidhean
- St. Louis, MO73 sgrùdaidhean
- Chicago, IL61 sgrùdaidhean
- Baltimore, MD60 sgrùdaidhean
- San Antonio, TX59 sgrùdaidhean
- Columbus, OH57 sgrùdaidhean
- Washington, DC55 sgrùdaidhean
Sgrùdaidhean eile ann an Mountain View
- Aillse (gach seòrsa)40 sgrùdaidhean
- Aillse a' bhroilleach26 sgrùdaidhean
- Ailse metastatach25 sgrùdaidhean
- Leukemia myeloid geur19 sgrùdaidhean
- Cancer Ovarian19 sgrùdaidhean
- Galar Speactram Autism17 sgrùdaidhean
- Ailseachadh nan Sgamhan17 sgrùdaidhean
- Aillse Prostata15 sgrùdaidhean
- Fàilligeadh a' Chridhe15 sgrùdaidhean
- Autism13 sgrùdaidhean
- Leukemia lymphoblastic geur13 sgrùdaidhean
- Aillse colorectal13 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.